Search Results - "Linch, Mark D"

mTORC2 targets AGC kinases through Sin1-dependent recruitment by Cameron, Angus J M, Linch, Mark D, Saurin, Adrian T, Escribano, Cristina, Parker, Peter J

“…The protein kinase TOR (target of rapamycin) is a key regulator of cell growth and metabolism with significant clinical relevance. In mammals, TOR signals…”
Get more information

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial by Hussain, Syed A, Lester, Jason F, Jackson, Richard, Gornall, Matthew, Qureshi, Muneeb, Elliott, Anthony, Crabb, Simon J, Huddart, Robert A, Vasudev, Naveen, Birtle, Alison J, Worlding, Jane, James, Nicholas D, Parikh, Omi, Vilarino-Varela, Maria, Alonzi, Roberto, Linch, Mark D, Riaz, Irbaz B, Catto, James W F, Powles, Thomas, Jones, Robert J

“…Recurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib…”
Get full text

Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment by Wong, Yien Ning Sophia, Joshi, Kroopa, Khetrapal, Pramit, Ismail, Mazlina, Reading, James L, Sunderland, Mariana Werner, Georgiou, Andrew, Furness, Andrew J S, Ben Aissa, Assma, Ghorani, Ehsan, Oakes, Theres, Uddin, Imran, Tan, Wei Shen, Feber, Andrew, McGovern, Ursula, Swanton, Charles, Freeman, Alex, Marafioti, Teresa, Briggs, Timothy P, Kelly, John D, Powles, Thomas, Peggs, Karl S, Chain, Benjamin M, Linch, Mark D, Quezada, Sergio A

“…Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to checkpoint blockade, highlighting a need to…”
Get full text

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D by Yu, Evan Y., Ferrario, Cristiano, Linch, Mark D., Stoeckle, Michael, Laguerre, Brigitte, Arranz, Jose A., Todenhöfer, Tilman, Fong, Peter C., Piulats, Josep M., Berry, William, Emmenegger, Urban, Mourey, Loic, Joshua, Anthony M., Mar, Nataliya, Appleman, Leonard J., Conter, Henry J., Gravis, Gwenaelle, Li, Xin Tong, Schloss, Charles, Poehlein, Christian, de Bono, Johann S.

“…Pembrolizumab plus abiraterone and prednisone exhibited antitumor activity and acceptable safety in patients with chemotherapy-naive metastatic…”
Get full text

Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial by Linch, Mark D., Wong, Yien Ning Sophia, Jones, Robert, Sankey, Peter, Josephs, Debra H., Crabb, Simon J., Staffurth, John, Zarkar, Anjali, White, Laura, Duggan, Marian, Pellizzari, Giulia, Wheeler, Graham, Beare, Sandy, Cartwright, Hayley, Linares, Josep, Akarca, Ayse, Quezada, Sergio A., Ensell, Leah, Hartley, John, Attard, Gerhardt, Burr, Joanna, Jayaram, Anuradha, Kularatne, Bihani, Kayani, Mahaz, Chung, Moon, Pritchard, Colin C., Freeman, Alex, Haider, Aiman, Marafioti, Teresa

“…Background: Responses to checkpoint inhibitor (CPI) monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) have been limited…”
Get full text

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients by Linch, Mark D., Jenner, Matthew W., Dines, Sharon, Davies, Faith E., Morgan, Gareth J.

“…Dexamethasone, thalidomide, etoposide and an antracycline have formed part of regimens such as DT-PACE which have demonstrated efficacy in previously treated…”
Get full text